Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $25.00

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) had its price target increased by equities researchers at Cantor Fitzgerald from $22.00 to $25.00 in a report issued on Friday, The Fly reports. Cantor Fitzgerald’s price target suggests a potential upside of 57.04% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Piper Sandler upped their price objective on shares of Catalyst Pharmaceuticals from $20.00 to $21.00 in a report on Tuesday, February 7th. HC Wainwright upped their price objective on shares of Catalyst Pharmaceuticals from $18.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, December 21st. StockNews.com assumed coverage on shares of Catalyst Pharmaceuticals in a report on Thursday. They set a “buy” rating on the stock. Finally, Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $18.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, January 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $15.92 on Friday. The company has a market capitalization of $1.66 billion, a PE ratio of 21.51 and a beta of 1.16. The company has a 50-day simple moving average of $16.41 and a two-hundred day simple moving average of $15.61. Catalyst Pharmaceuticals has a one year low of $6.15 and a one year high of $22.11.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Large investors have recently bought and sold shares of the company. SummerHaven Investment Management LLC boosted its position in Catalyst Pharmaceuticals by 0.7% in the 4th quarter. SummerHaven Investment Management LLC now owns 99,563 shares of the biopharmaceutical company’s stock worth $1,852,000 after purchasing an additional 723 shares in the last quarter. FMR LLC boosted its position in Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 822 shares in the last quarter. Jupiter Asset Management Ltd. boosted its position in Catalyst Pharmaceuticals by 1.9% in the 4th quarter. Jupiter Asset Management Ltd. now owns 47,245 shares of the biopharmaceutical company’s stock worth $878,000 after purchasing an additional 879 shares in the last quarter. HRT Financial LP boosted its position in Catalyst Pharmaceuticals by 2.7% in the 4th quarter. HRT Financial LP now owns 34,105 shares of the biopharmaceutical company’s stock worth $634,000 after purchasing an additional 888 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in Catalyst Pharmaceuticals by 6.0% in the 2nd quarter. Janney Montgomery Scott LLC now owns 17,772 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 86.66% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.